Abiopharma

🔍 Chacon Quiros Juan Jose (Director)

Company: ESTABLISHMENT LABS HOLDINGS INC. (ESTA)

Report Date: 2025-08-03

Detailed Transactions and Holdings:

• Acquired 10,285 shares of Common Shares (Direct)
  Date: 2025-08-03 | Code: A | equity_swap_involved: 0 | shares_owned_after: 224,433.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Shares (Direct)
  Date: 2025-08-03 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 1,078,264.00 | Footnotes: F2
• Acquired 14,906 shares of Stock Option (Right to buy) at $36.46 per share (Derivative)
  Date: 2025-08-03 | Code: A | Expires: 2035-05-14 | Exercise: 2026-06-01 | equity_swap_involved: 0 | shares_owned_after: 14,906.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: Represents an award of stock units under the Issuer's 2018 Equity Incentive Plan. One-fourth of the shares subject to the award shall vest on June 1, 2026 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through such date. The grant was contingent upon execution of a post-employment agreement, which was signed on August 3, 2025. Concurrently, the Reporting Person entered into a consulting agreement effective June 1, 2025.
• F2: The shares are held by Sariel Group Ltd. The Reporting Person is a shareholder of Sariel Group Ltd and has voting and dispositive power over the shares owned by Sariel Group Ltd. The Reporting Person disclaims beneficial ownership of the shares held by Sariel Group Ltd, except to the extent of his pecuniary interest therein.
• F3: One-fourth of the shares subject to the option shall vest on June 1, 2026 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.